drugset / Trial / NCT01802411

Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy

NCT01802411

Phase 3 Completed 191 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.

Timeline

Start
2012-12
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 266 mg Other

Indications

No indication recorded.